Hemoglobinopathies Market Worth to cross USD 14081.01 million By 2027

Posted On July 02, 2021     

The Global Hemoglobinopathies Market value is expected to grow by an impressive 10.5% of CAGR during the forecast period of 2021 to 2027. The market can grow to USD 14081.01 million by 2027 as per the report by Value Market Research. Hemoglobinopathy affects millions of people throughout in the world, present at low prevalence in all sizeable populations, and is particularly common among people whose ancestors come from sub-Saharan Africa, regions in the Western Hemisphere, India, Saudi Arabia, and Mediterranean countries. There is no widely available cure for these diseases. Some have been successfully treated with blood stem cell, transplantsor bone marrow. However, it is not widely done because of the difficulty in finding a matched donor. For these reasons, the development of new solution and therapies that can reliably diagnose is needed. The growing prevalence of the disease and the national control program are driving the need for new therapies. Health care systems are engaged in investigating and ensure that they can adequately address the many and complex lifelong needs of these patients.
 
Hemoglobinopathy refers to blood disorders and diseases that affect RBCs. It can be genetically determined abnormal change in the molecular structure of haemoglobin. This group of diseases and disorders includes haemoglobin C disease, haemoglobin S-C disease, sickle cell anaemia, and thalassemias. These disorders affect the number or shape of RBCs in the body, the symtoms can be very different from one another, can cause life-threatening symptoms while some causes mild or even no signs of the condition.

The detailed research study "Global Hemoglobinopathies Market Report By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants,) By Diagnosis (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants), By Therapy (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants) And By Regions - Industry Trends, Size, Share, Growth, Estimation And Forecast, 2021-2027" assists in understanding the market dynamics with qualitative as well as quantitative data.

On the basis of type the market is segmented into Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants. By diagnosis the hemoglobinopathies market is categorised as Thalassemia (Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others), Sickle Cell Disease (Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others), Other Hemoglobin (Hb) Variants (Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others).By therapy the hemoglobinopathies market is categorised as Thalassemia (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others), Sickle Cell Disease (Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others), Other Hemoglobin (Hb) Variants (Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others). The regions covered in the market study are North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. This section throws light on the geographical spread of revenue and/or volume of the hemoglobinopathies market.

The Report Segments Global Hemoglobinopathies Market -
By Type

  • Thalassemia
  • Sickle Cell Disease
  • Other Hemoglobin (Hb) Variants

 
By Diagnosis

  • Thalassemia (Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others)
  • Sickle Cell Disease (Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others)
  • Other Hemoglobin (Hb) Variants (Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others)

 
By Therapy

  • Thalassemia (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others)
  • Sickle Cell Disease (Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others)
  • Other Hemoglobin (Hb) Variants (Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others)

 
By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 
Players Profiled In the Report:
Sangamo Therapeutics, Inc., bluebird bio, Inc., Pfizer, Inc., Prolong Pharmaceuticals LLC, Gamida Cell, Global Blood Therapeutics, Inc., Emmaus Life Sciences Inc., Novartis AG, and Bioverativ Inc.

Download the FREE SAMPLE of Global Hemoglobinopathies Market Research Report

 
About Value Market Research -
Value Market Research was established with the vision to ease decision making and empower the strategists by providing them with holistic market information. Our analysts’ team is well equipped with all research tools and techniques and hold deep knowledge of the industry they are working for.

We ensure intellectual, precise and quality data is delivered to our client. We facilitate clients with syndicate research reports and customized research reports on 25+ industries with global as well as regional coverage.

Contact:
Value Market Research
401/402, TFM, Nagras Road, Aundh, Pune-7.
Maharashtra, INDIA.
Tel: +1-888-294-1147
Email: [email protected]
Website: https://www.valuemarketresearch.com

Why Choose Us

Client First Policy
Excellent Quality
Robust After Sales Support
24/7 Email Support

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Clients

Testimonials